Evidence map›Paper›PMID 42596824›Full record

ArticleMolecular medicine reports2026

Uric acid enhances tumor stemness in breast cancer cells by upregulating GMPS.

Zhiying Wang, Mingzhang Huang, Yuanqi Zhang, Siqi Huang, Wei Lei, Xiaorong Shui

Abstract read
In one paragraph

Article in Molecular medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Zhiying WangLaboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.
Mingzhang HuangLaboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.
Yuanqi ZhangDepartment of Breast Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.
Siqi HuangLaboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.
Wei LeiPrecision Medicine Center, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.
Xiaorong ShuiLaboratory of Vascular Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong 524001, P.R. China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic reprogramming is closely associated with the development and progression of cancer and is considered an emerging hallmark of cancer. To meet the bioenergetic and biosynthetic demands, tumor cells tend to initiate the metabolic reprogramming process, creating a tumor microenvironment that is adaptable for cancer cell growth and further promote oncogenic signaling, cell proliferation and metastasis. As a final byproduct of purine metabolism, the uric acid (UA) concentration rises in the quickly growing tumor microenvironment. However, whether elevated UA affects the development and prognosis of patients with tumors has not been demonstrated. In the present study, Cell Counting Kit‑8 and scratch healing test were used to investigate the effects of UA on the proliferation and migration of breast cancer cells. The effects of UA on nucleotide

Indexed as

Breast NeoplasmsNeoplastic Stem CellsUp-RegulationUric AcidCell Line, TumorCell MovementCell ProliferationFemaleGene Expression Regulation, NeoplasticHumansMetabolic ReprogrammingPeptide SynthasesPeptide Synthasesphosphoribosylaminoimidazole-succinocarboxamide synthetaseUric Acidbreast cancercyclic guanosine monophosphateguanosine 5'‑monophosphate synthasenucleotide de novo synthesistumor stemnessuric acid

Identifiers

PMID42596824
PMCPMC13501391

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.